fig3
Figure 3. Validation of the FRG recurrence prognostic index for the ferroptosis-induced response in PCa cells. (A) Expression profiles of genes in the FRG-based prognostic risk index for PCa recurrence, measured in two benign prostate cell types: immortalized Prostate Epithelial Cells (PrEC-LH) and Benign Prostatic Hyperplasia-1 cells (BPH-1), and in prostate adenocarcinoma cell lines: PC3, LNCAP, and VCAP. (B) RT-PCR verification of endogenous expression levels of the FRG risk model genes in PCa cell lines: PC3, DU145, C4-2, LNCAP, and VCAP. (C) Relative expression levels of FRG risk model genes in LNCAP and VCAP cells after exposure to DOX (0.5 μM) for 24 h. Actin was used as the reference gene for normalization, and the DMSO-treated group served as the control. *P < 0.05,
